CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Prostate Biopsy Specimen Analysis

Defines coverage criteria for pathological examination of prostate biopsy specimens (initial and repeat biopsies) and limitations for saturation biopsy; applies to provider billing and coverage determinations for Blue Cross Blue Shield - Tennessee members.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyProstate Biopsy Specimen Analysis

Policy CodePolicy N/A

Change TypeNo material changes noted

Effective DateN/A

Next Review DateN/A

Key ActionSubmit prostate biopsy specimens with one vial per sextant (max two cores per vial) and document MRI findings, biopsy approach, number of cores, and route.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12-corestandard extended sampling meeting coverage

saturationexplicitly does not meet coverage

one vial/sextantspecimen handling vial guidance

repeat biopsyrepeat biopsy when suspicion persists

>=2cores per MRI target

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Prostate Biopsy Specimen Analysis

Medically necessary biopsy specimen analysis

Covered when ALL of the following are met

Initial diagnostic biopsy: Pathological examination of tissue obtained from a prostate biopsy involving 12‑core extended sampling as a follow up to abnormal PSA, presence of a palpable nodule on digital rectal examination, or suspicious radiologic findings.12 cores (extended sampling)

One vial per sextant, no more than two cores per vial (per AUA specimen handling guidance).

Repeat biopsy after negative initial biopsy: Pathological examination of tissue from a follow-up prostate biopsy when clinical suspicion for prostate cancer persists; excludes prostate saturation biopsy.repeat biopsy (non-saturation)

Saturation biopsy is excluded from coverage (see exclusions).

Coverage and clinical criteria

Coverage guidance and clinical recommendations for biopsy and repeat biopsy

Initial biopsy approach when MRI available: For biopsy‑naïve patients with a suspicious lesion on pre‑biopsy MRI, perform targeted biopsies of the lesion and may also perform a systematic template (extended) biopsy.

Initial biopsy when MRI negative but elevated risk: If MRI shows no suspicious findings but the patient has elevated risk for clinically significant (GG2+) disease, proceed with a systematic (extended ≥12‑core) biopsy.

Repeat biopsy strategy after negative biopsy: Do not discontinue screening based solely on a negative biopsy or use only a PSA threshold to decide repeat biopsy. Re‑evaluate within the normal screening interval (2–4 years) or sooner based on risk and life expectancy; use risk assessment tools that incorporate the protective effect of a prior negative biopsy; consider biomarkers selectively when results would influence management. Immediate repeat biopsy is not recommended for focal (one‑core) HGPIN.

Repeat biopsy imaging guidance: Patients undergoing repeat biopsy who have not had a prior prostate MRI should obtain a prostate MRI before repeat biopsy. If MRI shows a suspicious lesion, perform targeted biopsies and may also perform a systematic template biopsy; if MRI shows no suspicious lesion, may proceed with systematic biopsy.

Pathological examination of tissue obtained from a prostate saturation biopsy does not meet coverage criteria. The policy states that while 12-core extended sampling for initial diagnostic biopsy and follow-up non-saturation repeat biopsies meet coverage criteria, pathological analysis of saturation biopsy specimens (extensive sampling up to ~24 cores) does not meet coverage criteria due to insufficient evidence of clinical benefit.

The National Comprehensive Cancer Network (NCCN) guidance noted in the references does not recommend a saturation biopsy strategy for all individuals with prior negative biopsies and states that an anteriorly directed biopsy is not supported in routine initial biopsy. NCCN recommends considering MRI followed by targeted biopsy for patients with persistent elevated PSA or prior negative biopsies, and favors MRI-targeted approaches over routine saturation sampling.

The listed evidence and guideline citation sections do not specify any additional explicit coverage exclusions beyond those stated in the policy language. References include major guideline and evidence sources (AUA, NCCN, ESMO, USPSTF, ACS) that inform the policy but do not themselves add separate coverage exclusions.

Saturation biopsy specimen analysis is considered not medically necessary / not covered in this policy. The document explains saturation biopsy involves extensive sampling (up to ~24 cores) and, although it may increase detection on repeat biopsy, there is insufficient published literature demonstrating required and beneficial impact for routine coverage of pathological examination of saturation biopsy specimens.

For patients with focal (one-core) high-grade prostatic intraepithelial neoplasia (HGPIN), guideline-based recommendations advise that clinicians should not perform an immediate repeat biopsy. Repeat biopsy decisions should instead be guided by overall risk assessment, imaging, and scheduled re-evaluation intervals.

The references and guideline citation lists included in the policy do not contain standalone statements labeled explicitly as 'not medically necessary' beyond the policy's own determinations. The scientific references are cited to support the clinical rationale rather than to list additional non-coverage declarations.

Procedure and Billing Codes

Applicable CPT/HCPCS Procedure Codesmixed

88305	Level IV - Surgical pathology, gross and microscopic examination.
G0416	Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method

mpMRI positive threshold — PI-RADS ≥3

mpMRI positive thresholdPI-RADS ≥3

Action promptedPerform targeted (systematic or non-systematic) biopsy when mpMRI is PI-RADS ≥3

When negativeIf mpMRI PI-RADS ≤2 and clinical suspicion is low, biopsy can be omitted

Provider Actions, Documentation, and Billing Guidance

Documentation Required

Conflicts with Government Policy

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. If there is a conflict between this policy and any applicable government policy (e.g., Medicare LCDs or NCDs, or state Medicaid), the government policy supersedes this policy and will be used to make the determination.

Government (Medicare/Medicaid LCD/NCD) policy supersedes this policy when applicable — verify member’s coverage and applicable federal/state determinations before adjudication.
For the most up-to-date Medicare policies and coverage, visit: https://www.cms.gov/medicare-coverage-database/search.aspx.

Note

References Include American Urological Association

Guidance and recommendations referenced in this policy include clinical standards from the American Urological Association (AUA) that inform optimal biopsy techniques and specimen handling.

AUA recommends a 12-core systematic sampling methodology incorporating apical and far-lateral cores and advises against routinely collecting more than 12 cores for standard systematic sampling.

Background and Clinical Context

Prostate cancer exists on a spectrum from indolent to aggressive disease. Biopsy is indicated for an elevated PSA, a palpable abnormality on digital rectal examination, or suspicious findings on imaging. The policy specifies that initial diagnostic biopsy using 12-core extended sampling meets coverage criteria when performed for these indications, and that repeat non-saturation biopsy is appropriate when clinical suspicion persists after a negative initial biopsy. Extended systematic sampling increases detection compared with sextant biopsy, while saturation biopsy (extensive sampling up to ~24 cores) is associated with higher complication rates and is not appropriate as routine initial screening.

Definitions

mpMRI definition — Multi-parametric magnetic resonance imaging of the prostate

TermmpMRI (Multi-parametric magnetic resonance imaging of the prostate)

ComponentsMultiparametric sequences including anatomical and functional imaging per institutional protocol

RoleUsed pre-biopsy to detect lesions suspicious for clinically significant prostate cancer (GG2+) and guide targeted biopsy

TRUS definition — Transrectal ultrasound-guided biopsy

TermTRUS (Transrectal ultrasound-guided biopsy)

TechniqueSystematic transrectal biopsy using ultrasound guidance; commonly used for template/extended pattern (eg, 12-core)

References and Guideline Citations

The policy's reference and guideline citation sections are provided to support the clinical and coverage statements but do not list any additional explicit coverage exclusions. Major cited sources (AUA, NCCN, ESMO, USPSTF, ACS and other studies) inform the recommendations on biopsy technique and use of MRI, without adding separate exclusion language beyond the policy determination that saturation biopsy specimen analysis is not covered.

Note

AUA guidance referenced

References cited include the American Urological Association guidance on optimal techniques of prostate biopsy and specimen handling, which supports the policy's recommendations on sampling and specimen submission.

AUA Optimal Techniques of Prostate Biopsy and Specimen Handling is cited
Other guideline and trial literature cited supporting MRI‑targeted and systematic approaches

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyProstate Biopsy Specimen Analysis

Policy CodePolicy N/A

Change TypeNo material changes noted

Effective DateN/A

Next Review DateN/A

Key ActionSubmit prostate biopsy specimens with one vial per sextant (max two cores per vial) and document MRI findings, biopsy approach, number of cores, and route.

SourceLink

On This Page

Biopsy technique and sampling: Obtain at least two needle biopsy cores per MRI target; may use software MRI‑ultrasound fusion when available; either transrectal or transperineal route is acceptable. NCCN recommends an extended systematic pattern of at least 12 cores for systematic biopsy.

Omit biopsy in select high‑PSA scenarios: For patients with PSA >50 ng/mL and no clinical concern for reversible causes, clinicians may omit prostate biopsy when biopsy poses significant procedural risk or when immediate cancer treatment is required (e.g., impending spinal cord compression).

AUA guidance informs specimen handling (one vial per sextant; ≤2 cores per vial).

Documentation Required

Imaging‑First Approach When Available

When available, an imaging-first approach using multiparametric MRI (mpMRI) is recommended to guide initial and repeat biopsy decisions and to reduce unnecessary biopsies. If MRI identifies suspicious lesions, targeted biopsy is recommended; if MRI is negative but clinical risk remains high, proceed with systematic biopsy.

Clinicians may use mpMRI prior to initial biopsy to increase detection of clinically significant (GG2+) prostate cancer.
For biopsy‑naïve patients with a suspicious MRI lesion, perform MRI-targeted biopsies and consider concomitant systematic template biopsy.
For repeat biopsy, obtain prostate MRI prior to biopsy if no prior MRI; if MRI shows a suspicious lesion, perform targeted biopsy (with ≥2 cores per MRI target) and may add systematic sampling.
If MRI is negative but elevated risk persists, proceed with systematic biopsy per clinical judgment.

Step Therapy

No Step Therapy or Prior Authorization Specified in References

No step therapy, prior authorization, or step-based prerequisites are specified in the referenced evidence and guideline citations for prostate biopsy pathology. Providers should follow member benefit requirements and payer-specific administrative rules where applicable.

No step therapy requirements are described in the cited guidelines or evidence.
This policy does not specify prior authorization requirements; check payer/member-specific administrative rules for any local prior authorization processes.

Denial Risk

Coverage Requirements for Biopsy Types

Coverage indications: Initial 12‑core extended sampling and follow‑up biopsies (excluding saturation biopsy) meet coverage criteria; pathological examination of tissue from saturation biopsy does not meet coverage criteria.

Initial 12‑core extended sampling biopsy meets coverage criteria for initial diagnosis following abnormal PSA, palpable nodule, or suspicious imaging.
Follow‑up prostate biopsy tissue examination meets coverage when clinical suspicion persists, excluding saturation biopsy.
Pathological examination of saturation biopsy tissue DOES NOT MEET COVERAGE CRITERIA and is subject to denial.

Documentation Required

Specimen Handling and Required Procedure Documentation

Specimen handling and biopsy technique expectations informed by AUA guidance and reimbursement recommendations should be documented and followed for appropriate adjudication.

Submit one vial per sextant with no more than two cores per vial.
Follow AUA‑recommended 12‑core systematic sampling (incorporate apical and far‑lateral cores).
Obtain at least two needle biopsy cores per MRI target when performing targeted biopsy.
Document biopsy route (transrectal vs transperineal), number of cores, targeted vs systematic approach, and MRI findings when applicable.

Billing Rule

Pathology Procedure Codes

Use the listed CPT/HCPCS codes for pathology billing of prostate needle biopsy gross and microscopic examinations. Procedure code lists in the policy are for general reference and may not be all‑inclusive.

Covered codes include: CPT 88305 (Level IV surgical pathology, gross and microscopic examination) and HCPCS G0416 (surgical pathology, gross and microscopic examinations, for prostate needle biopsy).
Verify coding and modifier usage per current CPT guidance and payer billing rules.

Compared historically with directed/targeted approaches in evidence and guideline references

Clinically significant prostate cancer — Implied as Grade Group 2+; MRI PI-RADS ≥3 prompts targeted biopsy

DefinitionClinically significant prostate cancer is implied as Grade Group (GG) 2 or higher (GG2+)

Imaging thresholdmpMRI PI-RADS ≥3 is considered positive and prompts targeted biopsy for detection of GG2+ disease

Clinical implicationUse MRI findings plus risk factors to decide between targeted and/or systematic biopsy

Multiparametric MRI-targeted biopsy — Biopsy approach using MRI-visible lesions to target cores

DefinitionMultiparametric MRI-targeted biopsy: biopsy approach using MRI-visible lesions to target cores

Technique detailsObtain at least two needle biopsy cores per MRI target; may use software MRI-ultrasound fusion when available

RoutesMay be performed via transrectal or transperineal approach and may be combined with a systematic template biopsy

Saturation biopsy — Strategy obtaining many cores (saturation); discussed but not recommended/covered

DefinitionSaturation biopsy: a strategy obtaining a larger number of cores (saturation) to improve cancer detection on initial or repeat evaluation

Typical core countsOften involves substantially more cores (eg, 20–24+ cores) compared with standard 12-core extended sampling

Coverage stancePathological examination of tissue from saturation biopsy does not meet coverage criteria and is considered not medically necessary